首页 | 本学科首页   官方微博 | 高级检索  
     

二甲双胍与瑞格列奈对初诊2型糖尿病治疗效果分析
引用本文:高仲尧. 二甲双胍与瑞格列奈对初诊2型糖尿病治疗效果分析[J]. 糖尿病新世界, 2021, 0(6): 96-98
作者姓名:高仲尧
作者单位:广东省中山市神湾医院内科
摘    要:目的 分析二甲双胍与瑞格列奈对初诊2型糖尿病治疗效果观察.方法 选择该院2018年7月—2020年7月实施治疗的初诊2型糖尿病患者88例,根据抽签法进行分组,分为对照组(二甲双胍,n=44)与研究组(二甲双胍联合瑞格列奈,n=44),对比分析两组血糖水平与不良反应,统计胰岛素相关指标.结果 在空腹血糖(FPG)、餐后2...

关 键 词:初诊2型糖尿病  二甲双胍  瑞格列奈  血糖水平

Analysis of the Therapeutic Effect of Metformin and Repaglinide on Newly Diagnosed Type 2 Diabetes
GAO Zhongyao. Analysis of the Therapeutic Effect of Metformin and Repaglinide on Newly Diagnosed Type 2 Diabetes[J]. Diabetes New World, 2021, 0(6): 96-98
Authors:GAO Zhongyao
Affiliation:(Department of Internal Medicine,Shenwan Hospital,Zhongshan,Guangdong Province,528462 China)
Abstract:Objective To analyze the therapeutic effect of metformin and repaglinide on newly diagnosed type 2 diabetes.Methods The 88 newly diagnosed type 2 diabetic patients who were selected for treatment from July 2018 to July 2020 in this hospital were divided into control group(metformin,n=44)and study group(metformin plus repaglinide,n=44)according to the lottery method,compared and analyzed the blood glucose levels and adverse reactions between the two groups,and count insulin-related indicators.Results The levels of fasting blood glucose(FPG),2 h postprandial blood glucose(2 hPG)and glycosylated hemoglobin(HbAlc)were lower in the study group than in the control group,the difference was statistically significant(P<0.05).In the incidence of adverse reactions,the study group was better than the control group,the difference was statistically significant(P<0.05).On HOMA-IR and HOMA-β,the study group was better than the control group,the difference was statistically significant(P<0.05).Conclusion Repaglinide combined with metformin for the first diagnosis of type 2 diabetes has an ideal effect.It plays an important role in controlling blood glucose levels and can be further promoted in clinical practice.
Keywords:Newly diagnosed type 2 diabetes  Metformin  Repaglinide  Blood glucose level
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号